These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26222073)

  • 1. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.
    Dvorak HF
    Cancer J; 2015; 21(4):237-43. PubMed ID: 26222073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.
    Nagy JA; Dvorak HF
    Clin Exp Metastasis; 2012 Oct; 29(7):657-62. PubMed ID: 22692562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF as a key mediator of angiogenesis in cancer.
    Carmeliet P
    Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.
    Sitohy B; Nagy JA; Jaminet SC; Dvorak HF
    Cancer Res; 2011 Nov; 71(22):7021-8. PubMed ID: 21937680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the VEGF/VEGFR axis in cancer biology and therapy.
    Rapisarda A; Melillo G
    Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
    Sitohy B; Nagy JA; Dvorak HF
    Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF as a therapeutic target in cancer.
    Ferrara N
    Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of the tumor vasculature.
    Nagy JA; Chang SH; Shih SC; Dvorak AM; Dvorak HF
    Semin Thromb Hemost; 2010 Apr; 36(3):321-31. PubMed ID: 20490982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition.
    Nagy JA; Brown LF; Senger DR; Lanir N; Van de Water L; Dvorak AM; Dvorak HF
    Biochim Biophys Acta; 1989 Feb; 948(3):305-26. PubMed ID: 2465781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumors: wounds that do not heal-redux.
    Dvorak HF
    Cancer Immunol Res; 2015 Jan; 3(1):1-11. PubMed ID: 25568067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenesis, anti-VEGF(R) and outlook.
    Petersen I
    Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease.
    Brown LF; Dvorak AM; Dvorak HF
    Am Rev Respir Dis; 1989 Oct; 140(4):1104-7. PubMed ID: 2478057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.